Intimation of publication of unaudited financial result pursuant to regulation 47 of SEBI for second quarter and half year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd informed BSE about the newspaper publication of its unaudited standalone financial results for Q2 FY26 and the half year ended 30 September 2025, in Financial Express (English) and Jan Satta (Hindi) on 16 November 2025. For H1 FY26, total income from operations stood at ₹1,087.08 lacs, down from ₹1,355.83 lacs in H1 FY25, a decline of roughly 20%. Despite the revenue drop, the company swung back to a net profit of ₹30.74 lacs in H1 FY26, compared to a loss of ₹179.81 lacs in H1 FY25. Q2 FY26 alone delivered a standalone profit after tax of ₹7.14 lacs versus a loss of ₹34.37 lacs in Q2 FY25. The results were reviewed by the Audit Committee and approved by the Board on 14 November 2025. The company operates in the pharmaceuticals business and reports only a single operating segment.
The top-line shrank meaningfully year-on-year, which is a concern, but the sharp turnaround from a sizeable loss to a small profit is a positive signal for shareholders. The filing itself is a routine regulatory disclosure, so no immediate stock price reaction is expected from the announcement alone.